{"title":"<i>HFE</i> and Non-<i>HFE</i> Hereditary Hemochromatosis Based on Screening of 854 Individuals: 12 Years of an Iranian Experience.","authors":"Razieh Zarifian Yeganeh, Masoumeh Akbari Kelishomi, Atiyeh Ahmadpour Jenaghard, Banafsheh Salmani, Zohreh Vahidi, Mina Makvand, Maryam Azad, Mahdieh Kooshki, Yassin Bouraqi, Azita Azarkeivan, Hossein Najmabadi, Maryam Neishabury","doi":"10.1089/gtmb.2023.0764","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Introduction:</i></b> The genetics of hereditary hemochromatosis (HH) is understudied in Iran. Here, we report the result of genetic screening of 854 individuals, referred as \"suspected cases of HH,\" to a diagnostic laboratory in Iran over a 12-year period. <b><i>Materials and Methods:</i></b> From 2011 to 2012, 121 cases were screened for HH using Sanger sequencing of <i>HFE</i> exons. After 2012, this method was replaced by a commercial reverse hybridization assay (RHA) targeting 18 variants in the <i>HFE</i>, <i>TFR2</i>, and <i>FPN1(SLC40A1)</i> genes and 733 cases were screened using this method. <b><i>Results:</i></b> From the total studied population, HH was confirmed by genetic diagnosis in only seven cases (0.82%): two homozygotes for <i>HFE</i>:C282Y and five homozygotes for <i>TFR2</i>:AVAQ 594-597 deletion. In 254 cases (29.7%), H63D, C282Y, S65C, and four other <i>HFE</i> variants not targeted by RHA were identified. Although the resulting genotypes in the latter cases did not confirm HH, some of them were known modifying factors of iron overload or could cause HH in combination with a possibly undetected variant. No variant was detected in 593 cases (69.4%). <b><i>Conclusion:</i></b> This study showed that the spectrum of genetic variants of HH in the Iranian population includes <i>HFE</i> and <i>TFR2</i> variants. However, HH was not confirmed in the majority (99.2%) of suspected cases. This could be explained by limitations of our genetic diagnostics and possible inaccuracies in clinical suspicion of HH. A cooperative clinical and genetic investigation is proposed as a solution to this issue.</p>","PeriodicalId":12603,"journal":{"name":"Genetic testing and molecular biomarkers","volume":" ","pages":"289-296"},"PeriodicalIF":1.1000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genetic testing and molecular biomarkers","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1089/gtmb.2023.0764","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/9 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The genetics of hereditary hemochromatosis (HH) is understudied in Iran. Here, we report the result of genetic screening of 854 individuals, referred as "suspected cases of HH," to a diagnostic laboratory in Iran over a 12-year period. Materials and Methods: From 2011 to 2012, 121 cases were screened for HH using Sanger sequencing of HFE exons. After 2012, this method was replaced by a commercial reverse hybridization assay (RHA) targeting 18 variants in the HFE, TFR2, and FPN1(SLC40A1) genes and 733 cases were screened using this method. Results: From the total studied population, HH was confirmed by genetic diagnosis in only seven cases (0.82%): two homozygotes for HFE:C282Y and five homozygotes for TFR2:AVAQ 594-597 deletion. In 254 cases (29.7%), H63D, C282Y, S65C, and four other HFE variants not targeted by RHA were identified. Although the resulting genotypes in the latter cases did not confirm HH, some of them were known modifying factors of iron overload or could cause HH in combination with a possibly undetected variant. No variant was detected in 593 cases (69.4%). Conclusion: This study showed that the spectrum of genetic variants of HH in the Iranian population includes HFE and TFR2 variants. However, HH was not confirmed in the majority (99.2%) of suspected cases. This could be explained by limitations of our genetic diagnostics and possible inaccuracies in clinical suspicion of HH. A cooperative clinical and genetic investigation is proposed as a solution to this issue.
期刊介绍:
Genetic Testing and Molecular Biomarkers is the leading peer-reviewed journal covering all aspects of human genetic testing including molecular biomarkers. The Journal provides a forum for the development of new technology; the application of testing to decision making in an increasingly varied set of clinical situations; ethical, legal, social, and economic aspects of genetic testing; and issues concerning effective genetic counseling. This is the definitive resource for researchers, clinicians, and scientists who develop, perform, and interpret genetic tests and their results.
Genetic Testing and Molecular Biomarkers coverage includes:
-Diagnosis across the life span-
Risk assessment-
Carrier detection in individuals, couples, and populations-
Novel methods and new instrumentation for genetic testing-
Results of molecular, biochemical, and cytogenetic testing-
Genetic counseling